[BIOC] Biocept, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.81 Change: 0.01 (0.97%)
Ext. hours: Change: 0 (0%)

chart BIOC

Refresh chart

Strongest Trends Summary For BIOC

BIOC is in the long-term down -96% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company?s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company is also developing other OncoCEE CTC tests, including OncoCEE-LU for lung cancer; OncoCEE-GA for gastric cancer; OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma. Biocept, Inc. sells its products through its direct sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States, as well as biopharma companies. It has collaboration agreement with Rosetta Genomics, Ltd. to evaluate microRNAs

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.65 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 689.47% Sales Growth - Q/Q97.37% P/E-0.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-69.57% ROE-107.05% ROI-80.02%
Current Ratio9.07 Quick Ratio8.98 Long Term Debt/Equity0.25 Debt Ratio0.16
Gross Margin-829.02% Operating Margin-5489.41% Net Profit Margin-5701.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.29 M Cash From Investing Activities-30 K Cash From Operating Activities-3.33 M Gross Profit-710 K
Net Profit-3.8 M Operating Profit-3.65 M Total Assets20.9 M Total Current Assets20.27 M
Total Current Liabilities2.23 M Total Debt130 K Total Liabilities7.32 M Total Revenue150 K
Technical Data
High 52 week10.8 Low 52 week0.28 Last close0.82 Last change1.25%
RSI35.25 Average true range0.06 Beta0.53 Volume88.26 K
Simple moving average 20 days-9.71% Simple moving average 50 days-20.38% Simple moving average 200 days-81.95%
Performance Data
Performance Week-10.07% Performance Month-19.61% Performance Quart-18.81% Performance Half-87.32%
Performance Year-6.82% Performance Year-to-date-83.09% Volatility daily3.09% Volatility weekly6.9%
Volatility monthly14.14% Volatility yearly48.98% Relative Volume119.54% Average Volume1.9 M
New High New Low


2019-11-07 08:05:00 | Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe

2019-11-06 08:05:00 | Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019

2019-11-04 08:05:00 | Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting

2019-10-14 10:05:49 | Why Biocept, Inc.'s NASDAQ:BIOC CEO Pay Matters To You

2019-10-07 08:05:00 | Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE

2019-10-03 08:05:00 | Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform

2019-09-03 08:05:00 | Biocept to Present at Two Investment Conferences in September

2019-08-22 08:05:00 | High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer

2019-08-13 08:05:00 | Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells

2019-08-12 16:05:00 | Biocept Reports Second Quarter 2019 Financial Results

2019-08-12 14:30:00 | Biocept, Inc. to Host Earnings Call

2019-08-05 08:05:00 | Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019

2019-07-22 08:05:00 | Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®

2019-07-16 13:31:27 | Does Biocept, Inc. NASDAQ:BIOC Have A High Beta?

2019-06-18 08:05:00 | Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel

2019-06-03 08:05:00 | Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4

2019-05-28 08:05:00 | Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally

2019-05-20 15:07:00 | Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer

2019-05-20 08:05:00 | Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer

2019-05-08 16:05:00 | Biocept Reports First Quarter 2019 Financial Results

2019-05-01 08:05:00 | Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019

2019-03-28 16:05:00 | Biocept Reports 2018 Fourth Quarter and Full Year Financial Results

2019-03-26 08:05:00 | Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment

2019-03-21 08:05:00 | Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019

2019-03-18 08:05:00 | Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device

2019-03-18 08:00:00 | Biocept, Potential Near-Term Catalysts for Biocept

2019-03-15 09:00:00 | Biocept Announces Pricing of $8.2 Million Registered Direct Offering

2019-03-13 08:05:00 | Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services

2019-03-04 08:05:00 | Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting

2019-02-27 10:00:00 | Four Healthcare Stocks Getting A Boost On Wednesday

2019-02-27 08:05:00 | Biocept and Providence Saint John's Health Center Collaborate to Evaluate Cerebrospinal Fluid for Use with Liquid Biopsy Testing in Metastatic Cancer

2019-02-20 08:05:00 | Biocept Issues Letter to Stockholders

2019-02-13 09:34:02 | What Makes Biocept BIOC a New Buy Stock

2019-02-08 08:45:00 | Biocept Announces Pricing of $7.5 Million Underwritten Public Offering

2019-02-07 08:42:00 | Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits

2019-02-05 08:05:00 | Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful

2019-01-30 08:20:00 | Biocept, Inc., Pipeline Review, Upcoming Catalysts and Milestones

2019-01-28 08:05:00 | Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA

2019-01-22 14:45:35 | Should You Worry About Biocept, Inc.’s NASDAQ:BIOC CEO Salary Level?

2019-01-18 09:00:00 | Biocept Announces Pricing of $2.2 Million Registered Direct Offering

2019-01-17 07:55:00 | Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept

2018-12-31 14:49:54 | Penny Stocks to Watch for January 2019

2018-12-19 06:55:00 | Today's Research Reports on Trending Tickers: Biogen and Biocept

2018-12-18 08:05:00 | Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology

2018-11-29 08:09:42 | The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved

2018-11-20 13:19:24 | What Kind Of Shareholder Appears On The Biocept Inc’s NASDAQ:BIOC Shareholder Register?

2018-11-13 16:05:00 | Biocept Reports Third Quarter 2018 Financial Results

2018-11-06 08:05:00 | Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018

2018-11-05 08:05:00 | Biocept Announces New Executive Hires to its Sales and Marketing Organization

2018-11-01 11:28:03 | Biocept BIOC May Report Negative Earnings: Know the Trend Ahead of Next Week's Release